Cargando…

Application of Nanoliposome Alprostadil in the Perioperative Period of Percutaneous Coronary Intervention to Reduce In-Stent Restenosis: A Systematic Review and Meta-Analysis

BACKGROUND: In-stent restenosis (ISR) is a common complication after percutaneous coronary intervention (PCI) surgery for patients with coronary atherosclerotic heart disease (CHD). Reports indicate alprostadil may reduce ISR, and this study aimed at reviewing and summarizing the effect of nanolipos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Decai, Wang, Dawei, Zhao, Zhen, Liu, Qingqing, Yang, Rongyuan, Liu, Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212678/ https://www.ncbi.nlm.nih.gov/pubmed/37251365 http://dx.doi.org/10.1155/2023/4100197

Ejemplares similares

In stent restenosis after percutaneous coronary intervention
por: Eyüboğlu, Mehmet
Publicado: (2016)

The number of stents was an independent risk of stent restenosis in patients undergoing percutaneous coronary intervention
por: Tang, Long, et al.
Publicado: (2019)

Impact of anemia on in-stent restenosis after percutaneous coronary intervention
por: Hu, Huilin, et al.
Publicado: (2021)

Factors Affecting In-stent Restenosis in Patients Undergoing Percutaneous Coronary Angioplasty
por: Sajadian, Mostafa, et al.
Publicado: (2018)

Hypersensitivity and in-stent restenosis in coronary stent materials
por: Hu, Wansong, et al.
Publicado: (2022)

Impact of hyperuricemia on clinical outcomes after percutaneous coronary intervention for in-stent restenosis
por: Joo, Hyung Joon, et al.
Publicado: (2018)

An analysis of factors related to the development of in-stent restenosis after percutaneous coronary intervention
por: Zhang, Gai, et al.
Publicado: (2020)

Risk factors associated with intra-stent restenosis after percutaneous coronary intervention
por: Alexandrescu, Dan-Mihai, et al.
Publicado: (2021)

Predictors of restenosis following percutaneous coronary stent implantation: The role of trimetazidine therapy
por: Csató, Gábor, et al.
Publicado: (2022)

In-stent restenosis after percutaneous coronary intervention: emerging knowledge on biological pathways
por: Pelliccia, Francesco, et al.
Publicado: (2023)

Systematic Review of Chinese Herbal Medicines for Preventing in-Stent Coronary Restenosis after Percutaneous Coronary Intervention
por: Zheng, Guo-Hua, et al.
Publicado: (2012)

Predictive Value of COPD History on In-Stent Restenosis in Coronary Arteries Following Percutaneous Coronary Intervention
por: Hou, Ling, et al.
Publicado: (2023)

New predictors of in-stent restenosis in patients with diabetes mellitus undergoing percutaneous coronary intervention with drug-eluting stent
por: Wang, Jian-Long, et al.
Publicado: (2018)

Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents
por: Zhu, Yong, et al.
Publicado: (2021)

Calculating the overall risk of within-stent restenosis after multilesion percutaneous coronary intervention
por: Parviz, Yasir, et al.
Publicado: (2013)

An analysis of factors related to the development of in-stent restenosis after percutaneous coronary intervention: Retraction
Publicado: (2020)

Arterial stiffness in patients with coronary artery disease: relation with in-stent restenosis following percutaneous coronary intervention
por: Prskalo, Zrinko, et al.
Publicado: (2016)

Incidence and risk factors of in-stent restenosis after percutaneous coronary intervention in patients from southern China
por: Li, Mingrui, et al.
Publicado: (2022)

Drug-Eluting Stent as an Option for Intractable In-Stent Coronary Restenosis
por: Hachinohe, Daisuke, et al.
Publicado: (2011)

Heavy Coronary Calcium Mimicking In-Stent Restenosis
por: Park, Jeong-Hwan, et al.
Publicado: (2011)

Albumin to globulin ratio was associated with in‐stent restenosis and revascularization events after percutaneous coronary intervention
por: Zhang, Rui, et al.
Publicado: (2022)

Serum glycated albumin is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents: An observational study
por: Lin, Xiao Long, et al.
Publicado: (2022)

Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis
por: Nojima, Yuhei, et al.
Publicado: (2014)

Combined use of hydration and alprostadil for preventing contrast-induced nephropathy following percutaneous coronary intervention in elderly patients
por: XU, RONG-HE, et al.
Publicado: (2013)

Treatment effect of metformin combined with atorvastatin in reducing in-stent restenosis after percutaneous coronary intervention in coronary artery disease patients with type 2 diabetic patients
por: Chen, Mingli, et al.
Publicado: (2022)

Clinical characteristics of early and late drug-eluting stent in-stent restenosis and mid-term prognosis after repeated percutaneous coronary intervention
por: Zheng, Jian-Feng, et al.
Publicado: (2020)

Diagnostic value of intraluminal stent enhancement in estimating coronary in-stent restenosis
por: Nogourani, Mehdi Karami, et al.
Publicado: (2020)

Nanoparticle Drug- and Gene-eluting Stents for the Prevention and Treatment of Coronary Restenosis
por: Yin, Rui-Xing, et al.
Publicado: (2014)

SOCS1 gene promoter methylation status is associated with in-stent restenosis after percutaneous coronary intervention
por: Zhou, Liang, et al.
Publicado: (2017)

The characteristics and risk factors of in-stent restenosis in patients with percutaneous coronary intervention: what can we do
por: Wang, Pengfei, et al.
Publicado: (2020)

Development and validation of a risk prediction nomogram for in-stent restenosis in patients undergoing percutaneous coronary intervention
por: He, Wenbo, et al.
Publicado: (2021)

Outcomes of Percutaneous Coronary Intervention for In‐Stent Restenosis Versus De Novo Lesions: A Meta‐Analysis
por: Elbadawi, Ayman, et al.
Publicado: (2023)

Vascular Endothelial Growth Factor Genetic Variant Is Associated with in-Stent Restenosis after Percutaneous Coronary Intervention
por: Asgarbeik, Saeedeh, et al.
Publicado: (2022)

Coated stents to prevent restenosis in coronary heart disease
por: Gorenoi, Vitali, et al.
Publicado: (2005)

Drug- and Gene-eluting Stents for Preventing Coronary Restenosis
por: Lekshmi, Kamali Manickavasagam, et al.
Publicado: (2017)

Treatment of coronary in-stent restenosis: a systematic review
por: Pleva, Leos, et al.
Publicado: (2018)

Diagnosis and management challenges of in-stent restenosis in coronary arteries
por: Alraies, M Chadi, et al.
Publicado: (2017)

The Value of Pre- and Post-Stenting Fractional Flow Reserve for Predicting Mid-Term Stent Restenosis Following Percutaneous Coronary Intervention (PCI)
por: Rai, Alireza, et al.
Publicado: (2016)

Triglyceride-glucose index for predicting repeat revascularization and in-stent restenosis in patients with chronic coronary syndrome undergoing percutaneous coronary intervention
por: Guo, Xuantong, et al.
Publicado: (2023)

Percutaneous Coronary Intervention: Safety of Methotrexate and Its Possible Benefits on Restenosis After Bare-Metal Stent Deployment
por: Gouveia, Viviane, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nrfn8gslfvtemb9sf65a3rhgg9